Notable
AR1001 · Early Alzheimer's Disease (Polaris-AD)
Primary endpoint(s) modified
Also in this update: Study completion moved earlier from Dec 2027 to Oct 2027
AriBio Co., Ltd.Phase 3 NCT05531526 Registry history of NCT05531526 on ClinicalTrials.gov (opens the registry)